The specific mechanisms underlying the restorative effects of adrenal chromaffin grafts in experimental parkinsonism are still obscure. Recent findings indicated an involvement of graft-induced trophic interactions in the course of recovery-related events. Evidence that basic fibroblast growth factor (bFGF), a potent trophic protein for neurons, (1) is present in chromaffin cells (Blottner et al., 1989) and (2) exerts trophic activities on embryonic mesencephalic neurons in vitro (Ferrari et al., 1989) provided the rationale for administering bFGF in gel foam implants unilaterally to the striatum of 1 -methyl-4-phenyl-1,2,3,8-tetrahydropyridine (MPTP) lesioned mice. Simultaneous bFGF/MPTP treatment diminished bilaterally the reduction of striatal dopamine (DA) levels observed in cytochrome c/MPTP-treated mice and led to an ipsilateral reappearance of tyrosine hydroxylase (TH)-like immunoreactive fibers, most notably adjacent to the implant, 2 weeks after the surgery. Determinations of TH activities and TH immunoblotting demonstrated that bFGF almost fully reversed the loss of TH activity on either side but restored TH protein more on the ipsilateral than on the contralateral side. Furthermore, differences in dihydroxyphenylacetic acid levels, which were about twice as high on the contralateral side yet still reduced with respect to untreated mice, supported our assumption that the molar TH activity was increased on the untreated side, possibly due to an intrinsic compensatory up-regulation. Delayed administration of bFGF starting 8 d after the MPTP treatment was equally effective with regard to morphological parameters. Our results suggest that bFGF partially prevents the deleterious chemical and morphological consequences of an MPTP-mediated nigrostriatal lesion. Thus, bFGF mimics at least the morphological effects of chromaffin cell grafts to the MPTPlesioned brain.
Grafting fetal neural tissue into the mammalian brain to promote functional recovery of damaged neuronal circuitries has received increasing attention in recent years. In animal models, it has been repeatedly confirmed that grafting may counteract the consequences of brain lesions, degenerative changes, and Recctvcd May 2, 1989 : revised Dec. 7. 1989 accepted Jan. 10. 1990 .
We wish to thank Heidi Hlawaty for excellent technical assistance. We are Indebted to Dr. lrina Wulle for indispensable advice and valuable discussions. Thts work was supported by grant neuroendocrine disorders or reverse behavioral deficits (Dunnett et al., 1983; Stenevi et al., 1984; Gibson and Kriegcr, 1985) . Parkinson's disease is regarded as a dopamine (DA) deficiency syndrome (Bernheimer et al., 1973) resulting from the dcgcneration of the nigrostriatal DA system. In animal models of Parkinson's disease, transplantation of fetal substantia nigra has been employed as a means for providing a new dopaminergic input to the host striatum (Perlow et al., 1979; Dunnett et al.. 198 1, 1983 ). An analogous approach to compensate for the depletion of DA is the grafting of pieces or cell suspensions of adrenal medulla into the lateral ventricles (Freed et al.. 1981; Becker and Freed, 1988) or directly into the striatum (PatclVaidya et al., 1985; Stromberg et al., 1985; Freed et al., 1986) . Although the intrastriatal chromaffrn grafts show modest survival (Freed et al., 1986; Bohn et al., 1987; Hansen et al.. 1988; Pezzoli et al., 1988) , they can ameliorate behavioral impairments in the DA-denervated rat striatum (Freed et al.. 198 I; Stromberg et al., 1985) and enhance the regeneration of the dopaminergic host system in 1-methyl-4-phenyl-l-2,3,6-tetrahydropyridine (MPTP)-treated mice and monkeys (Bohn et al., 1987; Fiandaca et al., 1988) . There is as yet no conclusive explanation with regard to the mechanisms responsible for the curative effects described above. Mechanisms other than the, probably insufficient, release of DA by the graft (Freed et al., 1983; Stromberg et al., 1984) as, for example. liberation of trophic factors and inflammation-related events have been implicated in the beneficial effects of the grafts (Bohn et al.. 1987; Fiandaca et al., 1988; Pezzoli et al.. 1988) .
The chromaffin cell has been shown to store and release various neurotrophic activities (Unsicker et al.. 1987a (Unsicker et al.. , 1989 . One of its more comprehensively studied neurotrophic proteins is basic fibroblast growth factor (bFGF). bFGF has been characterized as a 16-18 kDa protein with mitogenic properties for mesenchyme derived cells (Lobb and Fett, 1984) . More recently, bFGF has been found to possess neurotrophic activities for several central and peripheral neuron populations in vitro (Morrison et al., 1986; Walicke et al., 1986; Unsicker et al.. 1987b) and in viva (Otto et al., 1987 (Otto et al., , 1989 Anderson et al.. 1988; Blottner et al., 1989) . bFGF has been isolated from adrenals (Gospodarowicz et al., 1986) and there is evidence that immunoreactive bFGF is specifically enriched in chromaffin vesicles (Westermann et al., 1990) . These findings, along with the isolation of a striatal-derived neurotrophic factor (SDNF; Dal Toso et al., 1988) which shows striking biochemical similarities to bFGF, formed the basis for our hypothesis that adrenomedullary bFGF may be instrumental in fostering recovery associated with adrenal medulla grafts in animal models of parkinsonism.
MPTP is known to produce a transient neurotoxicity in the nigrostriatal dopaminergic system ofyoung adult mice (Heikkila et al., 1984; Hallmann et al., 1985; Ricaurte et al., 1986) and represents a useful tool to study experimental parkinsonism. The extent and intensity of the damage, as well as the evolution of recovery, are dependent on the dose and protocol of MPTP application Marsden and Jenner, 1987) .
In the present study we tried to mimic the effects of adrenal medulla grafts in MPTP-damaged C57BL/6 mice on the host dopaminergic system by administering bFGF via a gel foam implant. The recovery 2 weeks after MPTP treatment was assessed by tyrosine hydroxylase (TH) immunocytochemistry and by determining biochemical parameters of the dopaminergic system in the striatum.
Materials and Methods

MPTP treatment
Young adult male C57BU6 mice (Charles River Wiga, Sulzfeld, FRG) received 3 intraperitoneal injections of 30 mg/kg MPTP hydrochloride (Sigma) dissolved in 0.5 ml of 0.9% saline adjusted to pH 7.4 at 24 hr intervals. The first injection was given at the day of surgery or, for a delayed application of factors (see below), 8 d before the surgery. Control mice received injections of saline according to the same protocol.
Animal surgery
For studying the effects of bFGF on the lesioned dopaminergic system, the administration via a gel foam implant turned out to yield the most reproducible results. Under deep anesthesia (0.3 ml of 3.5% chloralhydrate), the skull of the right hemisphere was trepanated at a circumscribed area and the cortex covering the middle part of the striatum was removed by aspiration. When the bleeding had ceased, the gel foam implant (see next section) was placed into a prepared small cavity within the striatal parenchyme. The cortical wound cavity was filled with a piece of untreated gel foam before the skin was sutured. All animals had nostonerative survival times of 2 weeks. (Mtiller and Unsicker, 198 1) . Fifty microliters of the protein eluate were incubated for 30 min at 37°C with 50 11 ofa reaction mixture containing 0.17 mM L-tyrosine, 0.004 mM catalase, 0.025 mM o-benzylhydrazine, 0.19 mM 6,7-dimethyl-5,6,7,8-tetrahydropterine, 0.24 mM ascorbic acid, and 0.2 M sodium acetate buffer, pH 6.0. Control samples were boiled for 10 min. Reactions were terminated with 50 ~1 of 70% HClO,; adrenaline was added as an internal standard, and the samples were centrifuged for 5 min at 10,000 x g at 6°C. The enzymatically formed Dopa was extracted and quantified using the same procedure as for the DA measurements (see above).
TH immunocytochemistry
Chloralhydrate-anesthetized mice (naive, n = 3; MPTP, n = 4; MPTP/ cytochrome c, n = 6; MPTP/bFGF, n = 9; MPTP/bFGF delayed, n = 4) were perfused transcardially with a fixative containing 4% formaldehyde-0.2% picric acid in 0.1 M phosphate buffer (PB) at 4°C. Twentyfive-micron-thick frontal sections of the striatum were cut on a cryostat; every fifth section was washed in several changes of 0.1 M PB and further processed. Immunoperoxidase staining was performed with free-floating sections. Followingpreincubation, the sections were incubated with (1) anti-TH serum (Eugene Tech. Allendale: 1: 100) for 12 hr at 4°C. (2) anti-rabbit IgG (Sigma; 1:20) for 45 min at 20°C and (3) peroxidase: antiperoxidase (PAP) complex (Sigma; 1:50) for 45 min at 20°C. The tissue bound peroxidase was visualized by using diaminobenzidine as enzyme substrate. In control experiments, the primary antiserum was replaced by normal rabbit serum.
TH immunoblotting
Aliquots of the striatal homogenate (see above) were resolved by SDS-PAGE according to Laemmli (1970) . An aliauot of one animal was applied per lane, the protein content in all lanes being identical for each blot. Protein was determined by measuring the absorption at 280 nm. Separated proteins were electrophoretically transferred onto nitrocellulose filters (Towbin et al., 1979) , and blots were incubated with TH antiserum (see above) and peroxidase-conjugated second antibodies as described by Hawkes et al. (1982) . The TH immunoblotting was performed with 4 different sets of samples.
Cell culture
Administration of factors " "
Sterile pieces of gel foam (Spongostan, Ferrosan, Denmark; approx. 2-3 mm3) served as implants and contained the following proteins dissolved in saline: (1) 4 pg cytochrome c (Serva) as a nontrophic control protein and (2) 4 rg bFGF. Bovine recombinant bFGF was a generous gift of Dr. Knoerzer (Progen, Heidelberg, FRG) . Its biological activity was tested in a neuronal survival assay (Unsicker et al., 1987b ) and amounted to 3 trophic units (TU)/ng protein. As shown previously, the full quantity of factor contained in the gel foam could be eluted after 12 hr and retained its biological activity in an in vitro assay system (Otto et al., 1989 (Otto et al., ). et al., 1987b . Abo;t 200,000 cells were preplated for 1.5 hr in 2 ml of Ciliary ganglia (CC) were dissected from I-d-old chick embryos and DMEM (Dulbecco's Modified Eagles Medium; Gibco) and 10% fetal calf serum (FCS; Flow) on 35 mm Falcon petri dishes. The enriched dissociated into single cells accordina to oublished procedures (Unsicker neuron suspension (>90%) was seeded onto 96 well microtiter plates (Falcon) coated with poly-L-a-omithine (PORN)-laminin (gift of Dr. Mollenhauer, University of Erlangen, FRG) with a density of about 1000 neurons/well. Cultures were grown in DMEM with 0.25% BSA (Serva) and Nl additives (Bottenstein et al., 1980) for 24 hr. Plateau survival was established by supplementation of a saturating concentration of bFGF (10 &ml).
Quantitative determinations of DA, DOPAC, and TH activity Mice were killed by decapitation, and the striatum was rapidly dissected on ice. After weighing, the tissue was homogenized in 300 ~1 20 mM sodium acetate buffer with 0.1% T&on-X-100.
An aliquot was processed for analysis of DA and its metabolite dihydroxyphenylacetic acid (DOPAC), respectively. The remaining homogenate was taken for measurements of TH activities and immunoblot analysis. DA and DOPAC measurements. A 100 ~1 aliquot was added to 900 ~1 of 0.1 M sodium acetate buffer containing 1% T&on-X-100, 25 mM ethylenediaminotetraacetic acid (EDTA), and, as internal standard, N-methyl-dopamine. Following deproteinization with 50 ~1 HClO, (70%) and centrifugation, 100 ~1 of the supematant were processed by alumina extraction in triplicate. DA and DOPAC were detected by HPLC-ED (p-Bondapack-Cl8 column, 10 pm particle size; Waters system with pump 5 10; sample processor 740; Metrohm amperometric detector with glassy carbon electrodes at a potential of 0.72 V against a Ag/AgCl reference electrode) and quantified by comparison to the internal standard. Elution was performed with 50 mM HClO, containing 25 mM EDTA at a flow rate of 1.0-1.2 ml/min. TH activities. After centrifugation for 5 min (10,000 x g at 6°C) a 100 ~1 aliquot was gel-filtrated at 6°C using a Sephadex-G-25 column
The gel foam implants were removed from all mice taken for biochemical analysis and frozen at -80°C. For testing the biological activity contained in the wound fluid, each gel foam was eluted in 100 ~1 DMEM at 4°C overnight, and the eluate was centrifuged at 1000 rpm for 10 min to remove cellular debris. The supematant was tested in 25 ~1 aliquots per start well and titrated over 12 wells. Anti-bFGF-IgG (antibFGF antiserum was kindly provided by Dr. Biihlen; Pearl River, NY) recognizing bovine and rat bFGF were employed in a final dilution sufficient to block the activity of 40 r&ml bFGF on CG neurons. Twenty-four hours after seeding, the cultures were fixed with 2.5% glutaraldehyde in PB, and surviving neurite-bearing neurons were counted.
Results
Striatal DA levels To exclude that DA levels on the side of implantation (right) were reduced as a consequence of the surgery, mice were immediately decapitated after the operation and the striata separately processed for DA determination. A slight reduction was observed on the operated side, yet by 2 weeks DA levels (Table  1) were found to have returned to normal on this side and Results are given as means + SEM.
Gel foam was soaked with the indicated factors. The mice were killed 2 weeks after the surgery except for the group marked with one asterisk (*), which was killed immediately and analyzed for DA levels. Results are given as means f SEM. ap < 0.01 compared to data from MPTP/cytochrome c-treated mice (2-sided t test after analysis of variance).
slightly, but not significantly, to be elevated on the nonoperated side. Mice treated with cytochrome c without MPTP served as control group (100%).
Treatment with MPTP caused an 80% reduction of striatal DA levels in mice that had carried a cytochrome c implant for 2 weeks. This reduction was identical to that seen in unoperated MPTP-treated mice and lasted for at least 4 weeks (data not shown). Treatment with bFGF diminished this reduction significantly (p < 0.01) to 55% on the ipsilateral side and to 68% on the contralateral side. Absolute DA levels were equal on either side.
Eight days after MPTP treatment, DA content was diminished to 84% of controls (1.92 + 0.5 1 ng DA/mg tissue; n = 5). Thus, the completeness of the MPTP lesion has been verified before administering bFGF in a delayed regimen. (Fig. 1 a,  b) had virtually disappeared in the striata of the MPTP/cytochrome c treated group (Fig. lc, d ). The elevation of DA content due to bFGF application was paralleled by a notable reappearance of TH-IR fibers in the right, but not in the left striatum (Fig. 2) . The fiber density was especially high close to the implant within a zone of 150-200 pm (Fig. 2~ ) and decreased farther away from it (Fig. 2b) . In most animals we observed an increase in the TH fiber diameter adjacent to the bFGF-containing implant. The left striatum displayed sparse or no TH-IR fibers, which was, at first sight, not easily reconciled with DA levels paralleling those on the contralateral side. Explanations might be sought in discrepant TH immunoreactivity and synthetic activity (see next section and Discussion). Delayed application of bFGF a week after initiation of the MPTP lesion led to an identical TH-IR fiber pattern (cf Fig. 2 ), suggesting that bFGF is, in fact, capable of partially restoring a normal dopaminergic striatal innervation.
TH immunocytochemistry By 1 and 2 weeks the dense network of very fine TH-like immunoreactive (TH-IR) fibers visible in untreated mice
Striatal TH activity, DOPAC levels, and TH immunoblotting The finding that the striatal DA content could be restored to the same extent on both sides following unilateral bFGF application in MPTP-treated mice, although TH-IR fibers were only detectable on the ipsilateral side, pointed at different activities of the rate-limiting enzyme of the DA synthesis, i.e., TH. Therefore, we examined striatal TH activity, TH protein amounts, and levels of the DA decomposition product DOPAC. Analysis of these parameters allowed us to specify side differences in the DA metabolism.
TH activity. Determinations of the TH activity, as assessed by quantification of formed Dopa during 30 min of incubation, revealed a bilateral depletion of about 50% in MPTP/cytochrome c-treated mice as compared to controls (Table 2 ). This depletion was nearly fully reversed in MPTP/bFGF-treated animals, the activity on the side of treatment being only slightly higher than on the contralateral side.
TH immunoblotting. We used TH immunoblots of striatal homogenates for demonstrating in a semiquantitative manner different amounts of TH protein. A representative blot is shown in Figure 3 . In comparison to control mice, the TH amount appeared to be considerably reduced in MPTP/cytochrome c-treated mice as visualized by the width of the TH bands (Fig.  3, lanes 1 and 2) . Administration of bFGF apparently restored TH protein amounts on the ipsilateral side more than on the untreated side (Fig. 3, lanes 4 and 3) , where the TH protein amount appeared to be comparable to that of MPTP/cytochrome c-treated mice. Hence, the side variances in the TH protein amounts correlated with those observed with immunocytochemical methods (Figs. 1, 2) . DOPAC levels. In MPTP/cytochrome c-treated mice, DOPAC levels were depleted below the detection limit on either side (Table 3) . bFGF application increased the ipsilateral DOPAC content to about 25% of control levels. However, in the contralateral striatum, DOPAC levels were found to be twice as high, suggesting an elevated DA turnover. Figure 4 demonstrates the capacity of neurotrophic activities eluted from gel foam implants containing cytochrome c or bFGF, respectively, to promote the survival of cultured embryonic chick CG neurons. The eluates from either source maintained identical numbers of neurons as a saturating concentration of bFGF. However, addition of anti-bFGF antibodies in amounts sufficient to block 40 ng bFGF failed to reduce the survival and neurite-promoting activity eluted from the implants.
In vitro neurotrophic activities
Discussion
The neurotoxin MPTP generates clinical symptoms and neuropathological changes in humans which closely resemble Parkinson's disease (Ballard et al., 1985; Burns et al., 1985) . Similarly, primates and certain rodents are susceptible to MPTP and develop, at least transiently, characteristic neurodegenerative changes within the nigrostriatal system (Burns et al., 1983; Heikkila et al., 1984; Jenner et al., 1984) . In young adult mice, Insets depict areas close (a) and farther away (b) from the implant at higher magnification. Note the restoration (cf Fig. lc, d ) of the TH-IR fibers extending from the surface of the implant towards the corpus callosum (C') and within a 150-to 200-lrn-wide zone along the interface between implant and striatum. No recovery was observed on the contralateral side. Scale bar, 100 pm (insets, 25pm). MPTP treatment preferentially damages nerve endings, leaving the majority of cell bodies in the substantia nigra unaffected (Heikkila et al., 1984; Gupta et al., 1986; Ricaurte et al., 1986) . Extent and time course of the MPTP-induced damage are well documented in the C57BL/6 strain (SundstrGm et al., 1987 (SundstrGm et al., , 1988 . These conditions offer the possibility for studying the influence of specific factors on the recovery of the dopaminergic nigrostriatal system. Implantation of gel foam into the striatum generated an insignificant reduction of ipsilateral DA content immediately after the surgery, which returned to control levels by 2 weeks. The contralateral DA content was slightly increased above control levels. This observation already underscores the remarkable compensatory mechanisms (Hefti and Weiner, 1988) and plasticity (Bjiirklund and Stenevi, 1979) of the central dopaminergic system. The administration of 4 pg bFGF simultaneously with MPTP treatment or 1 week after initiation of the MPTP lesion caused a notable reappearance of ipsilateral TH-IR fibers adjacent to the implant but not on the contralateral side. This morphological recovery may be 'due either to a regrowth of degenerated nerve terminals and/or collateral sprouting of intact terminals. Moreover, a reexpression of TH-IR without any concomitant growth events might also account for this observation. It can be excluded, however, that the reappearance of TH-IR fibers resulted from the ingrowth of noradrenergic nerves since the noradrenaline content was unaltered. These morphological observations are comparable to those obtained after grafting adrenal medullary tissue in MPTP-treated mice (Bohn et al., 1987) and monkeys .
The evaluation ofthis bFGF-induced ipsilateral enhancement of TH-IR fibers turned out to be far more complex when looking at parameters concerning the DA metabolism (see Table 4 ). Interestingly, the DA content could be restored on both sides to the same level, that is, to 45% of controls. The contralateral elevation of DA content referred rather to the potency of compensatory mechanisms in this system than pointing at the existence of a diffusible factor. The DA content of the untreated left side initially appeared to be incompatible with the lack of TH-IR fibers. As the measured DA content represents the product of synthesis, degradation, storage, and release, we assumed an alteration of at least one of these parameters on the left as compared to the right side. We therefore looked for side differences in the TH content as well as in the specific TH activity and DOPAC content. The differences in the TH protein content assessed by immunoblots indicating that striata ipsilateral to bFGF treatment contained more TH than contralateral striata were in line with the TH-IR being present only in the ipsilateral striata. Despite the apparent lower TH content on the contra- lateral side, TH activity was equal on both sides. These results in conjunction with the evidence that DOPAC levels are higher in the contralateral striata suggest a higher molar TH activity on that side. The increase of the molar TH activity in striata contralateral to bFGF treatment may occur as a compensatory intrinsic mechanism (Acheson et al., 1980) to provide equal levels of the transmitter DA in both striata.
As mentioned above, the recovery in regard to morphology, i.e., partial reappearance ofTH-IR fibers, in this lesion paradigm (Bohn et al.. 1987 Peryoli et al., 1988) . This suggestion was based on the observation that in many cases the poor survival of grafts was not consistent with its putative curati\,c efrccts. This raised doubts about whether transplanted chromaffin cells were actually able to substitute for the lost 5triatal dopamine. a mechanism which had long been regarded as bclng responsible for the promotion of functional recovep. The ratlonalc for our conjecture that bFGF might be involved 111 graft-related recovery was provided by evidence that bFGF (I) is present in chromatfn tissue (Blottner et al.. 1989 : Westermann et al.. 1990 ) and (2) exerts neurotrophic activities in r/\'o as shown in various lesion models (Anderson et al., 1988; Blottner et al.. 1989 : Otto et al.. 1989 .
Supposedly. our data result from a combination of events including sprouting of fibers. cell survival. and regulatory processc5 in D.4 metabolism.
Certainly. our data do not permit the conclusion that bFGF is the agent d/rc~ct/~s responsible for these eft'ects. bFGF might have acted by inducing proliferation of astrogllal cells. as previously described after partial fimbriafijrnis transection and ventricular infusion of bFGF (Barotte et al.. 1989 (Giulian and Lachman. 1985; Lindholm et al.. 1987) . In our study. macrophage-like cells invading the gel foam implant ((~1. Figs. lc. d. and 2) were observed inconsistently and indepcndentll ofthe treatment. Studies are in progress to investigate in detail the possible responses ofastroglial. vascular, and bloodborne cells to bFGF in MPTP-lesioned mice. Interestingly.
the neurotrophic activities of the wound fluid collected from cytochrome c-and bFGF-treated mice contained approximatclq equal levels ofneurotrophic activities promoting embryonic chick ciliary ganglion survival and possessed strong neuritc-promoting activity. Both were not significantly inhibited b) the anti-bFGF-lgG.
It is unlikely that the antibodies might not ha\e recognized mouse bFGF given the extensive homologies of the mammalian bFGF sequences (Lobb. 1988) . Although bFGF is increased in CNS wounds (Finklestein et al.. 1988) . it IS conceivable that the cytochrome c-or bFGF-conraining gel foams in our experiments had taken up bFGF-mediatcd. CG-directed trophic agents.
bFGF has widespread distribution In the CNS (Janet ct al.. 1987) . and it may not be inferred from our findings that thrs protein is the physiological agent for nigrostriatal neurons. Even so, the rcccnt purification of a basic 14 K neurotrophic factor promoting in \Ytro survival and transmitter exprcsslon of embryonic mesencephalic DA neurons (Dal Toso ct al.. 1988 ) and the observation that bFGF mimics these cffccts (Ferraro ct al.. 1989) would be compatible with the notion of bFGF being a candidate factor in this neuronal system.
In conclusion. bFGF has been shown in this stud\ to I-c\ crse to some extent the chemical and morphological dcbcits within the nigrostriatal dopaminergic system which might be of retcvance to Parkinson's disease. It opens pcrspecti\es towards the possibility of eventually replacing brain grafts b> defined ncurotrophic and other factors and studying in more detail the local regulation of bFGF in the striatum of the normal and parklnsonian brain.
